Schneider J, Müller R, Buberl W, Kaffarnik H, Schubotz R, Hausmann L, Mühlfellner G, Mühlfellner O
Eur J Clin Pharmacol. 1979 Feb 19;15(1):15-9. doi: 10.1007/BF00563553.
In a double-blind, randomised, cross-over trial clofibrate and a combination of polyenyl phosphatidyl choline (PPC) plus clofibrate were tested in 67 patients with hyperlipoproteinemia. Each treatment lasted for 4 weeks and was separated by a 4 week placebo period. The daily doses were clofibrate 1.2 g and PPC 1.8 g + clofibrate 1.2 g. respectively. The results revealed that polypenyl phosphatidyl choline prevented the elevation of LDL-cholesterol induced by clofibrate treatment, and that the lipid-lowering potency of the combination did not differ significantly from that of clofibrate. Since elevation of LDL-cholesterol is considered to increase the risk of coronary heart disease, the combination appears to offer a therapeutic advantage. Despite the significance of this clinical observation, a final decision may only be obtained from a prospective, long term investigation in patients with coronary heart diseases and hyperlipoproteinemia.
在一项双盲、随机、交叉试验中，对67例高脂蛋白血症患者测试了氯贝丁酯以及多烯磷脂酰胆碱（PPC）加氯贝丁酯的组合。每种治疗持续4周，中间间隔4周的安慰剂期。每日剂量分别为氯贝丁酯1.2克和PPC 1.8克加氯贝丁酯1.2克。结果显示，多烯磷脂酰胆碱可防止氯贝丁酯治疗引起的低密度脂蛋白胆固醇升高，且该组合的降脂效力与氯贝丁酯无显著差异。由于低密度脂蛋白胆固醇升高被认为会增加冠心病风险，该组合似乎具有治疗优势。尽管这一临床观察结果具有重要意义，但只有通过对冠心病和高脂蛋白血症患者进行前瞻性长期研究才能得出最终结论。
